摘要
目的探讨艾司西酞普兰与米氮平治疗抑郁症的临床疗效比较。方法选择2018年3月~2020年3月我院收治的140例抑郁症患者作为研究对象,按随机数字表法分为对照组和研究组。研究组给予艾司西酞普兰治疗,对照组给予米氮平治疗。比较两组患者治疗前后的汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、匹兹堡睡眠质量指数量表(PSQI)、简明健康状况调查表(SF-36)评分及治疗后临床疗效和药物不良反应。结果研究组患者治疗后HAMD、HAMA、PSQI评分显著低于对照组,SF-36评分显著高于对照组(P<0.05);对照组总有效率(84.29%)显著低于研究组总有效率(95.71%),差异有统计学意义(P<0.05);研究组患者药物不良反应发生率显著低于对照组(P<0.05)。结论艾司西酞普兰更能有效改善患者不良情绪,提升患者的睡眠和生活质量,不良反应较少。
Objective To investigate the clinical efficacy of escitalopram and mirtazapine in the treatment of depression. Methods A total of 140 patients with depression from March 2018 to March 2020 were selected as the study subjects. They were randomly divided into the control group and the study group according to random number table method. The study group was treated with escitalopram and the control group was treated with mirtazapine. Hamilton depression scale(HAMD),Hamilton anxiety scale(HAMA),Pittsburgh sleep quality index(PSQI),36-item shotform health status survey(SF-36),clinical efficacy,adverse reactions in the two groups were compared. Results After treatment,HAMD,HAMA and PSQI scores in the study group were significantly lower than those in the control group,and sf-36 scores were significantly higher than those in the control group(P<0.05). The total effective rate in the control group(84.29%)was significantly lower than that in the study group(95.71%)(P<0.05). The incidence of adverse drug reactions in the study group was significantly lower than that in the control group(P<0.05). Conclusion Esitalopram can effectively improve patients’ bad mood,improve their sleep and quality of life,and less adverse reactions,clinical efficacy is better than mirtazapine.
作者
孙丽敏
SUN Limin(Liaocheng Fourth People's Hospital,Liaocheng 252000,China)
出处
《国际精神病学杂志》
2020年第3期495-497,共3页
Journal Of International Psychiatry
